萬嘉集團(00401.HK):擬以350萬元出售惠東養和腎析血液透析公司的全部股權
格隆匯3月31日丨萬嘉集團(00401.HK)公佈,2023年3月31日,公司全資附屬公司珠海升創醫療投資管理有限公司,擬向珠海雋藝科技有限公司出售目標公司惠東養和腎析血液透析有限公司的全部股權,代價為人民幣350萬元。
目標公司有權根據相關法律和法規開展血液透析業務及其營運。惠東中心乃目標集團目前在中國廣東省惠東經營的血液透析治療中心。
儘管自2022年底以來,中國政府不再對COVID-19採取任何措施,但中國仍爆發嚴重的COVID-19。這給中國所有地方政府(包括廣東省)帶來了沉重的醫療保險負擔。因此,患者可能就血液透析治療從醫療保險獲得補助而遇到困難。此外,惠東中心的租租賃物業裝修出現折舊。倘惠東中心將開始全面營運,目標公司須進一步注入資金以翻新和改進設備。惠東中心尚未就其正式血液透析治療營運取得許可證。預期申請程序通常耗時約兩至三年。因此,於取得必需的許可證前,惠東中心將不會開始營運。鑑於上述事項,董事認為,出售事項乃集團實現其於目標公司的投資的機會,否則,鑑於惠東中心的前景不明朗,集團須注入進一步資金以改善惠東中心的狀況。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.